
Lupin Limited announces FDA approval for its Abbreviated New Drug Application for Loteprednol Etabonate Ophthalmic Suspension, 0.5%, a generic equivalent to Lotemax® Ophthalmic Suspension, 0.5%, by Bausch & Lomb Inc. The product, manufactured in Lupin's Pithampur facility in India, is indicated for temporary relief of seasonal allergic conjunctivitis symptoms. Lotemax® had estimated annual sales of USD 59 million in the U.S. This approval enhances Lupin's portfolio and underscores its commitment to providing affordable healthcare solutions.
Like
Save
Share